Introduction: Blood pressure (BP) levels, beat-to-beat blood pressure variability, dynamic cerebral autoregulation and cardiac baroreceptor sensitivity are frequently abnormal following acute stroke and are associated with an adverse short- and long-term prognosis. Thiazide diuretics are effective antihypertensive agents in preventing primary and secondary stroke, but their hypotensive and cerebral autoregulatory effects in the immediate post-stroke period have not been studied. Methods: Thirty-seven hypertensive neuroradiologically proven ischaemic stroke patients were randomized in a double-blind, placebo controlled, parallel group study to bendrofluazide 2.5 mg daily or matching placebo, within 96 h of stroke onset, for a 7-day period. Casual and non-invasive beat-to-beat arterial BP levels, cerebral blood flow velocity, ECG and transcutaneous carbon dioxide levels were measured within 70 ± 20 h of cerebral infarction and again 7 days later. Dynamic cerebral autoregulatory indices, pulse interval, BP variability and cardiac baroreceptor sensitivity were also calculated. Results: Small, non-significant falls were seen in casual and beat-to-beat BP levels over the 7-day period in both active and placebo-treated patients with no differences between treatments. No significant changes were seen in dynamic cerebral autoregulation or in cardiac baroreceptor sensitivity during the follow-up in either group. Conclusion: Following acute ischaemic stroke, the standard dose of bendrofluazide at 2.5 mg daily in this study sample did not lower systemic BP levels over the subsequent 7-day period. There was no evidence that bendrofluazide significantly altered cerebral autoregulation or improved cardiac baroreceptor sensitivity post-ictus. Bendrofluazide appears to be an ineffective hypotensive agent at the standard dosage in the initial post-stroke period.

Keywords:
Stroke, Cerebral autoregulation, Bendrofluazide, Blood pressure
1.
Leonardi-Bee J, Bath PM, Phillips SJ, Sandercock PA: Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 2002;33:1315–1320.
2.
Harper G, Fotherby MD, Panayiotou BJ, Castleden CM, Potter JF: The changes in blood pressure after acute stroke: Abolishing the ‘white coat effect’ with 24-h ambulatory monitoring. J Intern Med 1994;235:343–346.
3.
Wallace JD, Levy LL: Blood pressure after stroke. JAMA 1981;246:2177–2180.
4.
Robinson TG, Dawson SL, Ahmed U, Manktelow B, Fotherby MD, Potter JF: Twenty-four hour systolic blood pressure predicts long-term mortality following acute stroke. J Hypertens 2001;19:2127–2134.
5.
Robinson TG, Waddington A, Ward-Close STN, Potter JF: The predictive role of 24-hour compared to casual blood pressure levels on outcome following acute stroke. Cerebrovasc Dis 1997;7:264–272.
6.
Dawson SL, Manktelow BN, Robinson TG, Panerai RB, Potter JF: Which parameters of beat-to-beat blood pressure and variability best predict early outcome after acute ischaemic stroke? Stroke 2000;31:463–468.
7.
Robinson TG, James M, Youde J, Panerai R, Potter J: Cardiac baroreceptor sensitivity is impaired after acute stroke. Stroke 1997;28:1671–1676.
8.
Robinson TG, Dawson SL, Eames PJ, Panerai RB, Potter JF: Cardiac baroreceptor sensitivity predicts long-term outcome after acute ischaemic stroke. Stroke 2003;34:705–712.
9.
Paulson OB, Strandgaard S, Edvinsson L: Cerebral autoregulation. Cerebrovasc Brain Metab Rev 1990;2:161–192.
10.
Dawson SL, Blake MJ, Panerai RB, Potter JF: Dynamic but not static cerebral autoregulation is impaired in acute ischaemic stroke. Cerebrovasc Dis 2000;10:126–132.
11.
Eames PJ, Blake MJ, Dawson SL, Panerai RB, Potter JF: Dynamic cerebral autoregulation and beat to beat blood pressure control are impaired in acute ischaemic stroke. J Neurol Neurosurg Psychiatry 2002;72:467–472.
12.
Vasoactive drugs for acute stroke. Cochrane Database Syst Rev 2000;CD002839.
13.
Bamford J, Sandercock P, Dennis M, Burn J, Warlow C: Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991;337:1521–1526.
14.
O’Brien E, Coats A, Owens P, Petrie J, Padfield PL, Littler WA, de Swiet M, Mee F: Use and interpretation of ambulatory blood pressure monitoring: Recommendations of the British hypertension society. BMJ 2000;320:1128–1134.
15.
Aaslid R, Markwalder TM, Nornes H: Noninvasive transcranial Doppler ultrasound recording of flow velocity in basal cerebral arteries. J Neurosurg 1982;57:769–774.
16.
Tiecks FP, Lam AM, Aaslid R, Newell DW: Comparison of static and dynamic cerebral autoregulation measurements. Stroke 1995;26:1014–1019.
17.
Robinson TG, Potter JF: Blood pressure and acute stroke. Age and Ageing 2004;33:6–12.
18.
Lavin P: Management of hypertension in patients with acute stroke. Arch Intern Med 1986;146:66–68.
19.
Powers WJ: Acute hypertension after stroke: the scientific basis for treatment decisions. Neurology 1993;43:461–467.
20.
Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhaupl K, Diener H.C, Dominiak P.The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003;34:1699–1703.
21.
Dyker AG, Grosset DG, Lees K: Perindopril reduces blood pressure but not cerebral blood flow in patients with recent cerebral ischemic stroke. Stroke 1997;28:580–583.
22.
Lisk DR, Grotta JC, Lamki LM, Tran HD, Taylor JW, Molony DA, Barron BJ: Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Arch Neurol 1993;50:855–862.
23.
Bath PM, Pathansali R, Iddenden R, Bath FJ: The effect of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure and platelet function in acute stroke. Cerebrovasc Dis 2001;11:265–272.
24.
Carlsen JE, Kober L, Torp-Pedersen T, Johansen P: Relation between dose of bendrofluazide, anti-hypertensive effect, and adverse biochemical effects. BMJ 1990;300:975–978.
25.
Giller CA, Bowman G, Dyer H, Mootz L, Krippner W: Cerebral arterial diameters during changes in blood pressure and carbon dioxide during craniotomy. Neurosurgery 1993;32:737–741.
26.
Serrador JM, Picot PA, Rutt BK, Shoemaker JK, Bondar RL: MRI measures of middle cerebral artery diameter in conscious humans during simulated orthostasis. Stroke 2000;31:1672–1678.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.